Predict your next investment

HEALTHCARE | Medical Devices & Equipment
haloneuro.com

See what CB Insights has to offer

Founded Year

2013

Stage

Acquired | Acquired

Total Raised

$24.9M

About Halo Neuroscience

Halo Neuroscience is developing a neuroscience-based technology for enhancing performance on cognitive tasks, for the healthy and impaired. The company aims to make a product that is an instant, safe, temporary neuromodulation regime that makes brains work better, faster, more accurately in the specific ways chosen.On February 9th, 2021, Halo Neuroscience was acquired by Flow Neuroscience. The terms of the transaction were not disclosed.

Halo Neuroscience Headquarter Location

735 Market Street 4th Floor

San Francisco, California, 94103,

United States

415-851-3338

Latest Halo Neuroscience News

Neuromodulation therapy may improve treatment-resistant depression

Nov 9, 2021

Disclosures: Williams reports being a named inventor on Stanford-owned intellectual property relating to accelerated TMS pulse pattern sequences and neuroimaging-based TMS targeting, having served on scientific advisory boards for Halo Neuroscience, NeuraWell, Nooma and Otsuka and having equity/stock options in Magnus Medical, NeuraWell and Nooma. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio A high dose of intermittent theta-burst stimulation with functional-connectivity-guided targeting outperformed sham stimulation for treatment-resistant depression. Researchers reported the results of the intervention, called Stanford Neuromodulation Therapy (SNT), in a double-blind randomized controlled trial published in American Journal of Psychiatry. “Repetitive transcranial magnetic stimulation (rTMS) has been available for over a decade, but its full potential for altering brain function in a positive, non-invasive way had yet to be discovered,” co-author Nolan R. Williams, MD, of the department of psychiatry and behavioral sciences at Stanford University, told Healio Psychiatry. “The FDA had approved a 6-week treatment course for patients with treatment-resistant depression, but it had modest efficacy, with the minority of patients experiencing remission of symptoms in controlled trials. However, it was clear there was vast potential in the technology.” Williams and colleagues sought to address the limitations of this prior research by developing SNT, formerly referred to as Stanford accelerated intelligent neuromodulation therapy (SAINT), which requires 5 days. In a prior study, researchers found that 90% of participants showed remission of symptoms, “a clear sign that SAINT had promise,” Williams said. In the current sham-controlled double-blind trial of SNT, Williams and colleagues tested the intervention among participants with treatment-resistant depression with current moderate-to-severe depressive episodes. They randomly assigned participants to active (n = 14) or sham (n = 15) SNT and used resting-state functional MRI to individually target the region of the left dorsolateral prefrontal cortex with the strongest functional anticorrelation with the subgenual anterior cingulate cortex. Montgomery-Åsberg Depression Rating Scale (MADRS) 4 weeks after treatment served as the primary outcome. Results showed a mean percent reduction from baseline in MADRS score 4 weeks after treatment of 52.5% in the active treatment group vs. 11.1% in the sham treatment group. “There is an immediate need for a treatment like this in emergency situations,” Williams said. “As a society, we often treat mental health emergencies differently than other acute health issues. Part of that has to do with the lack of available treatments.” Williams also noted that although additional studies are needed to replicate the findings of the current study, SNT may eventually be used in hospital settings to stabilize suicidal patients . “Studies have shown the highest risk of suicide is actually in the weeks following a discharge,” Williams said. “With SNT, it’s possible that patients may be discharged after the 5-day treatment with improved mood and feeling safe.” Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Halo Neuroscience

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Halo Neuroscience in 1 CB Insights research brief, most recently on Jan 28, 2019.

Expert Collections containing Halo Neuroscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Halo Neuroscience is included in 5 Expert Collections, including Wearable Computing.

W

Wearable Computing

378 items

Wearable computing is broadly defined as companies developing devices worn or placed on the body that are equipped with technology, which can range from wearable medical devices to AR/VR headsets to GPS pet collars.

C

Conference Exhibitors

6,062 items

Companies that will be exhibiting at CES 2018

I

Internet of Things ( IoT )

3,149 items

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

S

Smart Home & Consumer Electronics

1,085 items

This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.

Halo Neuroscience Patents

Halo Neuroscience has filed 36 patents.

The 3 most popular patent topics include:

  • Neurophysiology
  • Neurotechnology
  • Electrotherapy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/22/2019

9/21/2021

Neurotechnology, Electrotherapy, Neurophysiology, Electrical signal connectors, Electrophysiology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/22/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/21/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Neurotechnology, Electrotherapy, Neurophysiology, Electrical signal connectors, Electrophysiology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Halo Neuroscience Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Halo Neuroscience Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.